NASDAQ:ITCIIntra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ITCI shares have increased by 11.6% and is now trading at $19.8250.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Intra-Cellular Therapies.

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Intra-Cellular Therapies.

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.20. The biopharmaceutical company had revenue of $1.08 million for the quarter, compared to analysts' expectations of $1.75 million.
View Intra-Cellular Therapies' earnings history.

9 brokerages have issued 12 month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $68.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $38.43 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies.

News coverage about ITCI stock has been trending negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a news impact score of -2.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Intra-Cellular Therapies.

Some companies that are related to Intra-Cellular Therapies include Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Schrodinger (SDGR), Legend Biotech (LEGN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), HYPERA S A/S (HYPMY), Myokardia (MYOK), Evotec (EVTCY), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR) and Biohaven Pharmaceutical (BHVN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), AbbVie (ABBV), Clovis Oncology (CLVS), Novavax (NVAX), Myovant Sciences (MYOV), ACADIA Pharmaceuticals (ACAD) and Karyopharm Therapeutics (KPTI).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.86%), Rhenman & Partners Asset Management AB (0.71%), Assenagon Asset Management S.A. (0.40%), Raymond James & Associates (0.25%), SG Americas Securities LLC (0.05%) and Premier Asset Management LLC (0.03%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates.
View institutional ownership trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Rhenman & Partners Asset Management AB, UBS Group AG, and Premier Asset Management LLC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates.
View insider buying and selling activity for Intra-Cellular Therapies.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Raymond James & Associates, SG Americas Securities LLC, M&T Bank Corp, Strs Ohio, Gemmer Asset Management LLC, Zurcher Kantonalbank Zurich Cantonalbank , and Nisa Investment Advisors LLC.
View insider buying and selling activity for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $19.83.

Intra-Cellular Therapies has a market capitalization of $1.32 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]